Anybody read the S-3?
Excerpt: << Two identical, double blinded, randomized placebo-controlled Phase III clinical trials began in the second quarter of 1998. These studies, which include 52 patients each, were designed to assess the activity of ATIII in restoring heparin sensitivity among heparin-resistant patients undergoing cardiac surgery requiring CPB. The first study, conducted at six medical centers in Germany and the United Kingdom, has been completed, and the primary clinical
endpoint was met. Seventy-nine percent of the patients who received ATIII did not require administration of fresh frozen plasma before undergoing CPB surgery in comparison to only eight percent of the placebo group. In addition, the drug was well tolerated by patients. Patient enrollment in the second study, which is being conducted in the United States and Europe, is expected to be completed in the first quarter of 2000. >>
Enjoy!
Joe |
